000290204 001__ 290204
000290204 005__ 20250814095538.0
000290204 0247_ $$2doi$$a10.1016/j.ijbiomac.2024.132268
000290204 0247_ $$2pmid$$apmid:38734336
000290204 0247_ $$2ISSN$$a0141-8130
000290204 0247_ $$2ISSN$$a1879-0003
000290204 037__ $$aDKFZ-2024-01037
000290204 041__ $$aEnglish
000290204 082__ $$a570
000290204 1001_ $$aAslam, Aqsa$$b0
000290204 245__ $$aPreparation, characterization and evaluation of HPβCD-PTX/PHB nanoparticles for pH-responsive, cytotoxic and apoptotic properties.
000290204 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2024
000290204 3367_ $$2DRIVER$$aarticle
000290204 3367_ $$2DataCite$$aOutput Types/Journal article
000290204 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1734098142_9063
000290204 3367_ $$2BibTeX$$aARTICLE
000290204 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290204 3367_ $$00$$2EndNote$$aJournal Article
000290204 500__ $$aVolume 270, Part 2, June 2024, 132268
000290204 520__ $$aPaclitaxel (PTX) is a potent anticancer drug. However, PTX exhibits extremely poor solubility in aqueous solution along with severe side effects. Therefore, in this study, an inclusion complex was prepared between PTX and hydroxypropyl-β-cyclodextrin (HPβCD) by solvent evaporation to enhance the drug's solubility. The HPβCD-PTX inclusion complex was then encapsulated in poly-3-hydroxybutyrate (PHB) to fabricate drug-loaded nanoparticles (HPβCD-PTX/PHB NPs) by nanoprecipitation. The HPβCD-PTX/PHB NPs depicted a higher release of PTX at pH 5.5 thus demonstrating a pH-dependent release profile. The cytotoxic properties of HPβCD-PTX/PHB NPs were tested against MCF-7, MDA-MB-231 and SW-620 cell lines. The cytotoxic potential of HPβCD-PTX/PHB NPs was 2.59-fold improved in MCF-7 cells in comparison to free PTX. Additionally, the HPβCD-PTX/PHB NPs improved the antimitotic (1.68-fold) and apoptotic (8.45-fold) effects of PTX in MCF-7 cells in comparison to PTX alone. In summary, these pH-responsive nanoparticles could be prospective carriers for enhancing the cytotoxic properties of PTX for the treatment of breast cancer.
000290204 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000290204 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290204 650_7 $$2Other$$aHPβCD-drug inclusion complex
000290204 650_7 $$2Other$$aNano-system
000290204 650_7 $$2Other$$aPHB
000290204 650_7 $$2Other$$aPaclitaxel
000290204 7001_ $$aMasood, Farha$$b1
000290204 7001_ $$aPerveen, Kousar$$b2
000290204 7001_ $$0P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aBerger, Martin$$b3
000290204 7001_ $$aPervaiz, Asim$$b4
000290204 7001_ $$0P:(DE-He78)8da28eac875d8c53905ac3f4393784b8$$aZepp, Michael$$b5
000290204 7001_ $$0P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aKlika, Karel D$$b6
000290204 7001_ $$aYasin, Tariq$$b7
000290204 7001_ $$aHameed, Abdul$$b8
000290204 773__ $$0PERI:(DE-600)1483284-7$$a10.1016/j.ijbiomac.2024.132268$$gp. 132268 -$$nPart 2$$p132268$$tInternational journal of biological macromolecules$$v270$$x0141-8130$$y2024
000290204 8564_ $$uhttps://inrepo02.dkfz.de/record/290204/files/1-s2.0-S0141813024030733-main.pdf
000290204 8564_ $$uhttps://inrepo02.dkfz.de/record/290204/files/1-s2.0-S0141813024030733-main.pdf?subformat=pdfa$$xpdfa
000290204 909CO $$ooai:inrepo02.dkfz.de:290204$$pVDB
000290204 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000290204 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8da28eac875d8c53905ac3f4393784b8$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000290204 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000290204 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000290204 9141_ $$y2024
000290204 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000290204 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J BIOL MACROMOL : 2022$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000290204 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J BIOL MACROMOL : 2022$$d2023-10-21
000290204 9201_ $$0I:(DE-He78)G401-20160331$$kG401$$lMolekulare Toxikologie und Chemotherapie$$x0
000290204 9201_ $$0I:(DE-He78)A390-20160331$$kA390$$lAG Wirkstoffforschung$$x1
000290204 980__ $$ajournal
000290204 980__ $$aVDB
000290204 980__ $$aI:(DE-He78)G401-20160331
000290204 980__ $$aI:(DE-He78)A390-20160331
000290204 980__ $$aUNRESTRICTED